A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

July 17, 2025

Study Completion Date

July 17, 2025

Conditions

Mild to Moderate Hypertension

Interventions

DRUG

Zilebesiran

Zilebesiran administered by subcutaneous (SC) injection

DRUG

Placebo

Placebo administered by SC injection

Trial Locations (3)

Clinical Trial Site, Fukuoka

Clinical Trial Site, Osaka

Clinical Trial Site, Tokyo